[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342143-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342143-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","analysis-of-concordance-between-next-generation-sequencing-assessment-of-microsatellite-instability-and-immunohistochemistry-mismatch-repair-from-solid-tumors","Analysis of Concordance Between Next-Generation Sequencing Assessment of Microsatellite Instability and Immunohistochemistry-Mismatch Repair From Solid Tumors","","August 2022 CAP guidance recommends immunohistochemistry (IHC) for mismatch repair defects in gastroesophageal, small bowel, or endometrial carcinoma rather than next-generation sequencing assessment of microsatellite instability (NGS-MSI), and indicates a preference for IHC in colorectal carcinoma. Concordance between NGS-MSI and IHC-MMR was evaluated across a very large cohort of solid tumors to determine discordance rates and clinical implications for patient outcomes and ICI eligibility.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/analysis-of-concordance-between-next-generation-sequencing-assessment-of-microsatellite-instability-and-immunohistochemistry-mismatch-repair-from-solid-tumors/342143/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/analysis-of-concordance-between-next-generation-sequencing-assessment-of-microsatellite-instability-and-immunohistochemistry-mismatch-repair-from-solid-tumors/342143.png","ImageObject",300,407,{"name":42,"@type":43},"Evangeline","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the 2022 CAP guideline recommend regarding MSI assessment for ICI eligibility?","Question",{"text":63,"@type":64},"It recommends using immunohistochemistry (IHC) to test for mismatch repair defects in gastroesophageal, small bowel, or endometrial carcinoma over NGS-MSI, and states a preference to use IHC over NGS-MSI in colorectal carcinoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was concordance between NGS-MSI and IHC-MMR measured in this study?",{"text":68,"@type":64},"The study assessed concordance between NGS-MSI and IHC-MMR across a very large cohort spanning the spectrum of solid tumors.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main outcome findings when NGS-MSI and IHC-MMR disagreed?",{"text":72,"@type":64},"A discordance rate of 0.31% was observed. NGS-MSI was noninferior to IHC-MMR, and overall survival and post-ICI survival were significantly longer for MMRd/MSI-H tumors compared with MMRp/MSS tumors, despite disagreement between assays.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342143,1790531358,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Original Reports | Cancer Genomics  \nAnalysis of Concordance Between Next-Generation Sequencing Assessment of Microsatellite Instability and Immunohistochemistry-Mismatch Repair From Solid Tumors  \nRouba Ali-Fehmi, MD1 ; Harris Benjamin Krause, PhD2 ; Robert T. Morris, MD3,4; John J. Wallbillich, MD3,4 ; Logan Corey, MD3,4;  \nSudeshna Bandyopadhyay, MD3,4; Mira Kheil, MD3,4 ; Leana Elbashir, MD3,4; Fadi Zaiem, MD3,4; M. Ruhul Quddus, MD5 ; Evi Abada, MD, MS3,5; Thomas Herzog, MD6 ; Anthony N. Karnezis, MD, PhD7 ; Emmanuel S. Antonarakis, MD8 ; Pashtoon Murtaza Kasi, MD, MS9 ;  \nShuanzeng Wei, MD, PhD10 ; Jeffrey Swensen, PhD2; Andrew Elliott, PhD2; Joanne Xiu, PhD2 ; Jaclyn Hechtman, MD2;  \nDavid Spetzler, MS, PhD, MBA2 ; Jim Abraham, PhD2 ; Milan Radovich, PhD2 ; George Sledge, MD2 ; Matthew J. Oberley, MD, PhD2 ; and David Bryant, MD, PhD2  \nDOI [https://doi.org/10.1200/PO.23.00648](https://doi.org/10.1200/PO.23.00648)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | The new CAP guideline published in August 2022 recommends using immunohistochemistry (IHC) to test for mismatch repair defects in gastroesophageal (GE), small bowel (SB), or endometrial carcinoma (EC) cancers over nextgeneration sequencing assessment of microsatellite instability (NGS-MSI) for immune checkpoint inhibitor (ICI) therapy eligibility and states there is a preference to use IHC over NGS-MSI in colorectal carcinoma (CRC) . |\n| METHODS | We assessed the concordance of NGS-MSI and IHC-MMR from a very large cohort across the spectrum of solid tumors. |\n| RESULTS | Of the over 190,000 samples with both NGS-MSI and IHC-MMR about 1,160 were initially ﬂagged as discordant. Of those samples initially ﬂagged as discordant, 50.9% remained discordant after being reviewed by an additional pathologist. This resulted in a ﬁnal discordance rate of 0.31%(590/191,767) . Among CRC, GE, SB and EC, 55.4% of mismatch repair proﬁcient/MSI high (MMRp/MSI-H) tumors had at least one somatic pathogenic mutation in an MMR gene or POLE. Mismatch repair deﬁcient/microsatellite stable (MMRd/ MSS) tumors had a signiﬁcantly lower rate of high tumor mutational burden than MMRp/MSI-H tumors. Across all solid tumors, MMRd/MSI-H tumors had signiﬁcantly longer overall survival (OS; hazard ratio [HR], 1.47, P \u003C .001) and post-ICI survival (HR, 1.82, P \u003C .001) as compared with MMRp/MSS tumors. The OS for theMMRd/MSS group was slightly worse compared to theMMRp/MSI-H tumors, but this difference was not statistically signiﬁcant (HR, 0.73, P 5 .058), with a similar pattern when looking at post-ICI survival (HR, 0.43, P 5 .155) . |\n| CONCLUSION | This study demonstrates that NGS-MSI is noninferior to IHC-MMR and can identify MSI-H tumors that IHC-MMR is unable to detect and conversely IHC-MMR can identify MMRd tumors that NGS-MSI misses. |\n\nACCOMPANYING CONTENT  \n Appendix  \nAccepted August 12, 2024 Published November 20, 2024  \nJCO Precis Oncol 8:e2300648 © 2024 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nMLH1/PMS2 and MSH2/MSH6 are proteins that form heterodimers and play a critical role and in the recognition and initiation of DNA mismatch repair (MMR).1 Expression of the MMR proteins can be assessed directly via immunohistochemistry (IHC) and categorized as MMR proﬁcient (MMRp) or MMR deﬁcient (MMRd) . Microsatellite instability (MSI) status can also be assessed via polymerase chain reaction (PCR) or next-generation sequencing (NGS)3,4 and categorized as MSI high (MSI-H) or microsatellite stable (MSS) . PCR-MSI or NGS-MSI is highly correlated with IHC-deﬁned  \nMMR status (IHC-MMR) .5-9 MMRd/MSI-H tumors can beneﬁt from treatment with immune checkpoint inhibitors (ICIs) .10 An advantage of using NGS-MSI is that many patients are already undergoing NGS to identify somatic mutations that could inform the treatment they receive; assaying for MSI status at the same time reduces tissue consumption although IHC may","cbCainykjkAdLnuS","https://ap.wps.com/l/cbCainykjkAdLnuS","pdf",1268790,29,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What does the 2022 CAP guideline recommend regarding MSI assessment for ICI eligibility?\",\"answer\":\"It recommends using immunohistochemistry (IHC) to test for mismatch repair defects in gastroesophageal, small bowel, or endometrial carcinoma over NGS-MSI, and states a preference to use IHC over NGS-MSI in colorectal carcinoma.\"},{\"question\":\"How was concordance between NGS-MSI and IHC-MMR measured in this study?\",\"answer\":\"The study assessed concordance between NGS-MSI and IHC-MMR across a very large cohort spanning the spectrum of solid tumors.\"},{\"question\":\"What were the main outcome findings when NGS-MSI and IHC-MMR disagreed?\",\"answer\":\"A discordance rate of 0.31% was observed. NGS-MSI was noninferior to IHC-MMR, and overall survival and post-ICI survival were significantly longer for MMRd/MSI-H tumors compared with MMRp/MSS tumors, despite disagreement between assays.\"}]","Analysis of Concordance Between Next-Generation Sequencing Assessment of Microsatellite Instability and Immunohistochemistry-Mismatch Repair From Solid Tumors | PDF",1790045475,73,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32f4e1c5c5d839be0921118b244ec4b1.webp",983,1315,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aae15826eb3ddbb1f8f617e6251fe028.webp",982,1314,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65589bab8f6bffc94258c29a1099748a.webp",981,1312,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31e94b1b3619733fabef8b7fa94bbdac.webp",980,1311]